Background Cardiovascular disease (CVD) remains an important cause of mortality and
morbidity, and high levels of blood cholesterol are thought to be the major modifiable risk …

Background The addition of ezetimibe to statin therapy has been widely demonstrated to
significantly reduce low-density lipoprotein cholesterol levels. However, the efficacy of …

Background The comparative effects of statins, ezetimibe with or without statins and
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors remain unassessed. Design …

Clinicians inevitably encounter patients who meet the diagnostic criteria for the metabolic
syndrome (MetS); these criteria include central obesity, hypertension, atherogenic …

Introduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)–
related morbidity and mortality. However, a large proportion of patients cannot attain the …

Purpose Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the
United States. Recently published cholesterol treatment guidelines emphasize the use of …

Introduction Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of
statin users currently reach their lipid goals. In addition, statin treatment alone has relatively …

Background Ezetimibe, as a cholesterol absorption inhibitor, has been shown protecting
against atherosclerosis when combined with statin. However, side by side comparison has …

Background: Statins reduce the incidence of cardiovascular events, but no randomized trial
has investigated the best statins for secondary prevention. We compared the efficacy of …

Dyslipidemia, particularly increased low-density lipoprotein cholesterol (LDL-C) levels, are
associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD) events …